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background:  Conventional risk scores for ST-elevation myocardial infarction (STEMI) rely on clinical characteristics and extent of coronary 
artery disease (CAD). Whether high-sensitive cardiac troponin-T (hs-cTnT) and N-terminal B-type natriuretic peptide (NT-proBNP) measurements at 
admission improve risk stratification of invasively treated STEMI patients remains unclear.
methods: This PLATO biomarker substudy included 5385 invasively treated STEMI patients. Spearman correlation quantified associations between 
biomarkers and extent of CAD (number of vessels diseased >50%). The baseline Cox proportional hazards model included conventional risk factors 
(age, medical history, physiological parameters, cystatin C and treatment arm). Subsequently, extent of CAD and log transformed biomarkers were 
added (both in combination and individually) and models were compared with C-statistic, likelihood ratio test and net reclassification index (NRI). 
Focus lay on cardiovascular death and spontaneous myocardial infarction (MI), as a composite and individually.
results: Admission NT-proBNP (median 221 pmol/L, IQR 780) correlated to extent of CAD (ρ 0.13, p<0.001) while Hs-cTnT (median 147 ng/L, 
IQR 542) did not. Biomarkers correlated strongly (ρ 0.58, p<0.001). Hs-cTnT, NT-proBNP and extent of CAD were univariably associated with the 
composite endpoint and with cardiovascular death. Only NT-proBNP and extent of CAD were associated with spontaneous MI. Risk prediction of the 
composite endpoint was improved by addition of extent of CAD (Initial C-index of 0.69 to 0.71, NRI 0.25, p<0.001). Subsequent addition of NT-
proBNP (C-index 0.72, NRI 0.33, p<0.001) or hs-cTnT (C-index 0.71, NRI 0.19, p<0.001) further improved the model, but hs-cTnT did not add value 
over NT-proBNP. Prediction of cardiovascular death was improved by all measures, separately and combined (C-index 0.80), while only NT-proBNP 
improved prediction of spontaneous MI (C-index 0.67).
Conclusion: Cardiac biomarkers improved the risk stratification of invasively treated STEMI patients. When measured at admission, NT-proBNP 
outperforms hs-cTnT. 
